ARCHIVES

Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 5 | May 31, 2013

Download PDF Visit The Full Archive

Related Articles

Group Chairmen Criticize NCI Budget Priorities

July 11, 2003

Breast Cancer Overview Correlates Incidence Increase With Other Factors

July 29, 1988

President Drops Revision Plan; NCI To Receive $937.1 Million Voted By Congress For FY 1979

January 12, 1979

Ibrutinib Shows Disease Control In Elderly, High-Risk CLL Patients

April 26, 2013

Group trials need prioritization, review, NCI official says.

July 25, 2003

Pittsburgh Cancer Institute Wins SPORE Grant For Lung Cancer, For Three Major Projects.

July 20, 2001